KARBAPENEMLERE DİRENÇLİ GRAM- NEGATİF BASİL ...

23. White Friedrich L, Burgess D, Warkentın D, Bosso J. Comperative in vitro
pharmacodynamics of imipenem and meropenem against Pseudomonas aeruginosa.
Antimicrob Agents Chemother 1996;40(4).904-8.
24. Gür D. Beta-laktamazlar. Flora 1997;283:3-16.
25. Yang, Livermore DM. Interactions of meropenem with class C chromozomal beta-
lactamases. J Antimicrob Chemother 1989;24(Suppl A):187-96.
26. Kitzis MD, Acar JF, Gutmann L. Antibacterial activity of meropenem against gram-
negative bacteria with a permeability defect and against staphylococci. J Antimicrob
Chemother 1989;24 (suppl A):125-32.
27. Sumita Y, Fukasawa M, Okuda T. Comparison of two carpapenems, SM-7338 and
imipenem: affinities for penicillin-binding proteins and its release from these
proteins in Staphylococcus aureus. Antimicrob Agents and Chemother
1990;34(3):484-6.
28. Gür D. Gram-Negatif Bakterilerde Antibakteriyel Direnç Mekanizmaları. In: Ulusoy
S, Leblebicioğlu H, Arman D (editörler). Önemli ve sorunlu gram-negatif bakteri
infeksiyonları. Ankara, 2004:69-83.
29. Malouin F, Bryan LE. Modification of penicillin-binding proteins as mechanisms of
beta-lactam resistance. Antimicrob Agents Chemother 1986;30:1-5.
30. Spratt BG. Resistance to beta-lactam antibiotics mediated by alterations of
penicillin-binding proteins. In: Bryan LE (Ed.). Handbook of Experimental
Pharmacology. Berlin: Springer-Verlag, 1989:77-100.
31. Livermore DM. Mechanisms of resistance to beta-lactam antibiotics. Scand J Infect
Dis 1991;(Suppl 78):7-16.
32. Sanders CC. Beta-lactamases of gram-negative bacteria: New challenges for new
drugs. Clin İnfect Dis 1992;14:1089-99.
33. Sanders CC, Sanders WE. Beta-lactam resistance in gram-negative bacteria: Global
trends and clinical impact. Clin Infect Dis 1992;15:824-39.
34. Bradford PA. Extended-spectrum beta-lactamases in the 21 st century:
Charactarization, epidemiology and detection of this important resistance threat.
Clin Microbial Rev 2001;14:933-51.
51